MannKind CEO Is Optimistic About Near-Term Approval of Afrezza
This article was originally published in The Pink Sheet Daily
Executive Summary
One industry watcher at the J.P. Morgan conference says the company is like a "teenager," there's always an explanation.
You may also be interested in...
Pfizer's Message To Wall Street: We're Doing Things Differently Now
Exubera's failure was a defining moment for CEO Jeff Kindler, who says the episode motivated him to transform the way Pfizer makes decisions.
An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.